Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
Current Neuropharmacology
|
June 20, 2017
Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications
Rainer Kraehenmann
Current Topics in Behavioral Neurosciences
|
April 27, 2017
Experimental Psychosis Research and Schizophrenia-Similarities and Dissimilarities in Psychopathology
Leo Hermle, Rainer Kraehenmann
Frontiers in Human Neuroscience
|
July 13, 2018
Neuropsychodynamic Approach to Depression: Integrating Resting State Dysfunctions of the Brain and Disturbed Self-Related Processes
Heinz Boeker, Rainer Kraehenmann
Plos One
|
October 11, 2012
Crowding deficits in the visual periphery of schizophrenia patients
Rainer Kraehenmann, Franz X Vollenweider, Erich Seifritz, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
February 15, 2016
Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience
Thomas Pokorny, Katrin H Preller, Rainer Kraehenmann, et al.
Frontiers in Psychiatry
|
December 21, 2018
Early Linguistic Markers of Trauma-Specific Processing Predict Post-trauma Adjustment
Birgit Kleim, Andrea B Horn, Rainer Kraehenmann, et al.
Frontiers in Psychology
|
August 23, 2018
Too Imperfect to Fall Asleep: Perfectionism, Pre-sleep Counterfactual Processing, and Insomnia
Ralph E Schmidt, Delphine S Courvoisier, Stéphane Cullati, et al.
Human Brain Mapping
|
February 27, 2016
Ketamine administration reduces amygdalo-hippocampal reactivity to emotional stimulation
Milan Scheidegger, Anke Henning, Martin Walter, et al.
Neuroimage
|
July 17, 2017
Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow
Candace R Lewis, Katrin H Preller, Rainer Kraehenmann, et al.
Neuroimage. Clinical
|
February 25, 2016
The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity
Rainer Kraehenmann, André Schmidt, Karl Friston, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
Current Neuropharmacology
|
June 20, 2017
Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications
Rainer Kraehenmann
Current Topics in Behavioral Neurosciences
|
April 27, 2017
Experimental Psychosis Research and Schizophrenia-Similarities and Dissimilarities in Psychopathology
Leo Hermle, Rainer Kraehenmann
Frontiers in Human Neuroscience
|
July 13, 2018
Neuropsychodynamic Approach to Depression: Integrating Resting State Dysfunctions of the Brain and Disturbed Self-Related Processes
Heinz Boeker, Rainer Kraehenmann
Plos One
|
October 11, 2012
Crowding deficits in the visual periphery of schizophrenia patients
Rainer Kraehenmann, Franz X Vollenweider, Erich Seifritz, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
February 15, 2016
Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience
Thomas Pokorny, Katrin H Preller, Rainer Kraehenmann, et al.
Frontiers in Psychiatry
|
December 21, 2018
Early Linguistic Markers of Trauma-Specific Processing Predict Post-trauma Adjustment
Birgit Kleim, Andrea B Horn, Rainer Kraehenmann, et al.
Frontiers in Psychology
|
August 23, 2018
Too Imperfect to Fall Asleep: Perfectionism, Pre-sleep Counterfactual Processing, and Insomnia
Ralph E Schmidt, Delphine S Courvoisier, Stéphane Cullati, et al.
Human Brain Mapping
|
February 27, 2016
Ketamine administration reduces amygdalo-hippocampal reactivity to emotional stimulation
Milan Scheidegger, Anke Henning, Martin Walter, et al.
Neuroimage
|
July 17, 2017
Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow
Candace R Lewis, Katrin H Preller, Rainer Kraehenmann, et al.
Neuroimage. Clinical
|
February 25, 2016
The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity
Rainer Kraehenmann, André Schmidt, Karl Friston, et al.
Page
of 3